Unknown PHASE2 INTERVENTIONAL 1-arm NCT02949258

Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer (NCT-B4)

A Phase II Study of Neoadjuvant Chemotherapy With SEEOX Regimen Via Intra-arterial and Intravenous Administration Followed by Surgery for Borrmann Type 4 Gastric Cancer

Sponsor: Jinling Hospital, China

Conditions Gastric Cancer Stomach Neoplasms

Interventions S1 epirubicin etoposide oxaliplatin

Updated 5 times since 2017 Last updated: Oct 27, 2016 Started: Jan 31, 2017 Primary completion: Jan 31, 2019 Completion: Jan 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastric Cancer and Stomach Neoplasms and is currently ongoing. Jinling Hospital, China leads this study, which shows 5 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE2
Jan 2017 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jinling Hospital, China

Data source: Jinling Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China